Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials

Overview of attention for article published in Frontiers in oncology, January 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 55 Dimensions

Readers on

mendeley: 23 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 3 X users, with an upper bound of 14,704 followers.

RT @FrontOncology: 📣 Neoadjuvant EGFR-TKI therapy provides a feasible treatment modality for patients with resectable or potentially resect…

09 Jan 2022

Reply Repost Favourite

📣 Neoadjuvant EGFR-TKI therapy provides a feasible treatment modality for patients with resectable or potentially resectable EGFR-mutant #NSCLC Find out more in this systematic review by Li Sun et al. #OpenAccess article 👉 https://t.co/CiV3qbePvc #LungC

09 Jan 2022

Reply Repost Favourite

RT @filimasini: Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Tr…

12 Feb 2021

Reply Repost Favourite

Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials https://t.co/QfZi8GiXav

12 Feb 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.